ArticleEcancermedicalscience2026
Validation of Onco-MPI and Geriatric-8 for predicting 2-year mortality in older Indian patients with breast cancer: a prospective observational study.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Identifying vulnerabilities in older patients through comprehensive geriatric assessment is crucial but resource-intensive. This prospective study validated shorter tools- Onco-multidimensional prognostic index (MPI) and Geriatric-8 (G8) for predicting 2-year mortality in breast cancer patients and developed a nomogram using significant clinical predictors. Methods: The geriatric assessment was done in newly diagnosed treatment-naïve breast cancer patients with age ≥65 years. Overall survival was analysed by Kaplan-Meier test; univariate and multivariate analyses done to determine predictors of survival using Cox-proportional hazards model. A nomogram was constructed based on multivariate model and validated using calibration curve. Results: Among 300 patients (median age 70 years, IQR 67-74), 95.6% had ECOG-PS 0-1. High-grade histology and lympho-vascular invasion (LVI) positivity were seen in 77% and 30%, respectively. Most patients (77.6%) were non-metastatic. Luminal, HER2+ and triple negative subtype was present in 70%, 10.3% and 18.7% tumours. Rate of non-compliance to treatment was 25%. At median follow-up of 28.8 months, 2-year survival was 78%. The 2-year mortality for Onco-MPI categories was 13.36% (low-risk), 25.9% (medium-risk) and 29.8% (high-risk); high versus low-risk showed statistical difference (HR 2.68, 95% CI 1.13, 6.37; Conclusion: In elderly breast cancer patients, G8 score was a stronger predictor of survival, outperforming onco-MPI. The nomogram combining conventional prognostic factors with G8 showed good discrimination for pre-treatment prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.